Alzheimer's and Dementia
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Leveraging amino acid sensors as therapeutic targets for tauopathies and related dementias
2020
-
P4‐499: THE RETROGRADE TRANSPORT OF BDNF AND PRONGF DIMINISHES WITH AGE IN BASAL FOREBRAIN CHOLINERGIC NEURONS
2019
-
[O1–14–05]: SEX‐SPECIFIC CHANGES IN SYSTEMIC IMMUNE STATUS AND CENTRAL PATHOLOGY IN 3XTG‐AD MICE
2017
-
[P1–209]: NGF AND BDNF DYSMETABOLISM IN A TRANSGENIC RAT MODEL OF ALZHEIMER's DISEASE
2017
-
P4‐086: TAU Modulates BDNF Expression and Mediates Aβ‐Induced Bdnf Down‐Regulation in Animal and Cellular Models of Alzheimer's Disease
2016
-
P3‐189: BDNF downregulation in post mortem brain tissue of subjects with tauopathies
2009
-
P1‐345: BDNF mRNA levels are decreased in peripheral blood samples from subjects with Alzheimer's disease
2008
-
P1–032: Decreased BDNF mRNA levels in mouse models of Alzheimer's disease
2006
-
24-Hour Optimized Lighting for Persons with Dementia: Technology Development.
20.
2024
-
Basic Science and Pathogenesis..
20 Suppl 1:e084982.
2024
-
Clinical Manifestations..
20 Suppl 3:e093091.
2024
-
Clinical Manifestations..
20 Suppl 3:e087436.
2024
-
Combined population attributable fractions for dementia are dependent on strong assumptions of the form of interactions between risk factors: an analysis of data from the Canadian Longitudinal Study on Aging.
20:e087708.
2024
-
Defy Dementia: Mobilizing a Public Health Awareness Campaign for Dementia Prevention.
20:e089811.
2024
-
Dementia Care Practice..
20 Suppl 5:e087434.
2024
-
Diagnostic journey and barriers to diagnosis for patients with mild cognitive impairment or dementia due to Alzheimer’s disease in Canada: results from a real‐world survey.
20:e095446.
2024
-
Optimizing Dynamic White Lighting for practical application.
20:e088722.
2024
-
Optimizing Dynamic White Lighting for practical application.
20:e094243.
2024
-
Performance of a new instrument designed to assess medication use in cognitive impairment and dementia: A cross‐sectional analysis.
20:e087439.
2024
-
Treatment landscape and caregiver status for Alzheimer’s disease patients in Canada by disease severity: results from a real‐world survey.
20:e095444.
2024
-
Perivascular spaces, plasma GFAP, and speeded executive function in neurodegenerative diseases.
20:5800-5808.
2024
-
Distinct spatial contributions of amyloid pathology and cerebral small vessel disease to hippocampal morphology.
20:3687-3695.
2024
-
Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative.
20:1753-1770.
2024
-
A longitudinal study of care‐recipient relationship type on the quality of life in community‐dwelling older adults with dementia.
19.
2023
-
Challenges when monitoring and providing care to loved ones,Perspectives of Dementia caregivers in Canada.
19.
2023
-
Feasibility of a Synchronous, Remoted‐Delivered, Aerobic Exercise Training Program in Rural‐Dwelling Adults with Subjective Cognitive Decline ‐ The MN RIDE Pilot.
19.
2023
-
Formal Care Providers Experiences with Indigenous Understandings of the Stages of Dementia in Diverse Indigenous Communities in Canada and the United States.
19.
2023
-
Location Dynamics in Northern Rural Minnesota: Barriers and Facilitators for ADRD Diagnosis and Care.
19.
2023
-
Memory Keepers Medical Discovery Team: addressing Indigenous dementia disparities through deep exploration of culture and community‐specific context.
19.
2023
-
Modelling Latent Environmental Modifiers of Polygenic Risk for Late‐Life Depression Using Structural Equation Modelling.
19.
2023
-
Rare neurovascular genetic and imaging markers across neurodegenerative diseases.
19:5583-5595.
2023
-
Relational, Community Dementia Care for All: Observations and Lessons from On‐Reservation Providers, Administrators, and Formal Caregivers in the US and Canada.
19.
2023
-
Indigenous inclusion in the Canadian therapeutic platform trial for multidomain interventions to prevent dementia.
19.
2023
-
Relationships between polymorphisms in EPHX2, CYP2J2, CYP2C9, and CYP2C8, white matter hyperintensities, and regional atrophy.
19.
2023
-
Sex‐specific accumulation and therapeutic effect of the histone variant H2A.Z in Alzheimer’s disease.
19.
2023
-
The state of the art exercise recommendations for older adults with cognitive impairments: A meta‐analysis of the meta‐analysis.
19.
2023
-
Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid PET.
19:1503-1517.
2023
-
Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort.
19:226-243.
2023
-
Developing an Ethnographic Community‐Based Participatory Research Dementia Study with Diverse Indigenous Populations: Indigenous Cultural understandings of Alzheimer’s disease and related dementias – Research and Engagement (ICARE) project.
18.
2022
-
Exploring Traditional Healing and Medicine in Dementia Care for Indigenous Populations in North America, Australia, and New Zealand: A Policy Advocacy and Practice.
18.
2022
-
Gonadal Hormones Contribute to Sex Differences in Autoimmunity, Pathology and Behaviour in the 3×Tg‐AD Mouse Model of Alzheimer’s Disease.
18.
2022
-
Impact of a web‐based psychoeducational intervention on carer mental health quality of life: Results from a pragmatic randomized control trial.
18.
2022
-
Indigenous cultural understandings of Alzheimer’s disease and related dementias – research and engagement (ICARE): relationships between cultural strengths, education and stigma.
18.
2022
-
What does it take to get a diagnosis? Dementia recognition and diagnosis pathways among Indigenous peoples.
18.
2022
-
Neuropsychological, neuropsychiatric, and quality‐of‐life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
18:1314-1324.
2022
-
Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging..
18:88-102.
2022
-
Amyloid‐independent vascular contributions to cortical atrophy and cognition in a multi‐center mixed cohort with low to severe small vessel disease.
17.
2021
-
Development of an indigenous functional assessment (IFA) tool.
17:e054666.
2021
-
Driving and dementia: An “emotionally‐charged” issue for people with dementia and their multidisciplinary healthcare providers.
17:e051843.
2021
-
Impact of COVID‐19 on family care partners of persons with dementia in long‐term care settings in Canada: Not a ‘one‐size‐fits‐all’ story.
17:e052186.
2021
-
Mechanisms of neurodegeneration: How oxidative stress reduces proNGF axonal transport in basal forebrain cholinergic neurons.
17:e052362.
2021
-
Polygenic risk score for Alzheimer’s disease in Caribbean Hispanics.
17:e055031.
2021
-
Polymorphisms in EPHX2 and CYP2J2 moderate associations between white matter hyperintensities and temporal lobe atrophy.
17:e055592.
2021
-
Spontaneous blinking and brain health: Can blink‐related oscillations capture brain changes in aging?.
17.
2021
-
Traditional healing and medicine in dementia care for indigenous populations in North America, Australia, and New Zealand: A scoping review protocol.
17:e051066.
2021
-
Toward a theory‐based specification of non‐pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations.
17:255-270.
2021
-
Acceptability of a mental health care pathway to address dementia risk factors in primary care settings: A qualitative study.
16.
2020
-
Adaptation of the Canadian indigenous cognitive assessment in three provinces and evidence for validity.
16.
2020
-
Classification accuracy of the English version of the Canadian Indigenous Cognitive Assessment (CICA) in a majority culture memory clinic sample.
16.
2020
-
Cognitive impairment among community‐dwelling, off‐reserve indigenous populations in Canada.
16.
2020
-
Development and implementation of a training program to facilitate community partnerships in the Indigenous Cultural Understandings of Alzheimer’s Disease and Related Dementias – Research and Engagement (ICARE) project.
16.
2020
-
Exploring opportunities for the integration of traditional healing medicine in the care and prevention of dementia for first nations people from the Wiikwemikoong Unceded Territory on Manitoulin Island in Northern Ontario, Canada.
16.
2020
-
Neuropsychiatric symptom burden across neurodegenerative disorders and its association with function.
16.
2020
-
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study..
16:1412-1425.
2020
-
Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.
16:1182-1195.
2020
-
A roadmap to advance delirium research: Recommendations from the NIDUS Scientific Think Tank.
16:726-733.
2020
-
Cost‐effectiveness of a collaborative dementia care management—Results of a cluster‐randomized controlled trial.
15:1296-1308.
2019
-
F4‐06‐02: IMPROVING DEMENTIA OUTCOMES IN INDIAN COUNTRY: THE ONEIDA NATION ALZHEIMER'S DISEASE PROJECT.
15:p1227-p1227.
2019
-
O5‐08‐03: TRAJECTORIES OF HEALTH SYSTEM USE AND SURVIVAL FOR COMMUNITY‐DWELLING PERSONS WITH DEMENTIA: AN INCEPTION COHORT STUDY.
15:p1635-p1636.
2019
-
O5‐08‐06: COST‐EFFECTIVENESS OF A COLLABORATIVE DEMENTIA CARE MANAGEMENT – RESULTS OF A CLUSTER‐RANDOMIZED CONTROLLED TRIAL.
15:p1637-p1637.
2019
-
Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review.
14:1344-1376.
2018
-
P1‐603: MEASUREMENT INVARIANCE OF THE CENTRE FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE 10‐ITEM SHORT FORM (CES‐D‐10) IN THE CANADIAN LONGITUDINAL STUDY ON AGING.
14:p570-p570.
2018
-
P4‐165: COST‐UTILITY ANALYSIS OF DEMENTIA CARE MANAGEMENT: RESULTS OF THE CLUSTER‐RANDOMIZED, CONTROLLED, INTERVENTIONAL TRIAL DELPHI‐MV.
14:p1502-p1503.
2018
-
TD‐07‐03: SUPPORTING DEMENTIA TECHNOLOGY DEVELOPMENT IN INDIGENOUS COMMUNITIES IN CANADA: RESPECTING “THE WAY THAT WE ARE”.
14:p185-p185.
2018
-
Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study.
14:280-292.
2018
-
[P2–457]: SIGNS OF EARLY COGNITIVE DECLINE WITHIN CONNECTED SPEECH: EVIDENCE FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP).
13:p812-p814.
2017
-
[P2–497]: THE ROLE OF A KNOWLEDGE BROKER IN PROMOTING THE USE OF DEMENTIA CARE EVIDENCE IN CANADIAN RURAL HOME CARE CENTRES.
13:p831-p831.
2017
-
[P2–530]: DEMENTIA AMONG COMMUNITY‐DWELLING, OFF‐RESERVE INDIGENOUS POPULATIONS IN ONTARIO.
13:p845-p845.
2017
-
[P4–299]: BASE RATES OF IMPAIRED SCORES ARGUE AGAINST CORRECTION FOR MEDICAL CONDITIONS WITHIN A BRIEF NEUROPSYCHOLOGICAL BATTERY.
13:p1404-p1404.
2017
-
The Vascular Impairment of Cognition Classification Consensus Study.
13:624-633.
2017
-
F2‐03‐02: Primary Care Collaborative Memory Clinics in Ontario.
12:p218-p218.
2016
-
F3‐02‐01: Considerations in Culturally Safe Care for Indigenous People with Dementia In Canada.
12:p270-p271.
2016
-
F5‐03‐01: Biomarkers should be used in Clinical Care Based on Existing Effectiveness and Economic Evidence.
12:p370-p370.
2016
-
O3‐10‐04: Adapting the Kimberly Indigenous Cognitive Assessment for Use with Indigenous Older Adults in Canada.
12:p311-p311.
2016
-
O4‐12‐01: Feasibility of an Individualized Multifaceted Waking Intervention and its Effects on Functional Mobility, ADL Function and Quality of Life in Nursing Home Residents with Dementia.
12:p362-p363.
2016
-
P2‐050: Social Behaviours in The 5XFAD Mouse Model of Alzheimer's Disease.
12:p626-p626.
2016
-
P2‐301: Characteristics of Connected Language Subtypes in the Wisconsin Registry for Alzheimer's Prevention.
12:p749-p751.
2016
-
P2‐409: Primary Care Memory Clinics: What Elements of Care are Most Highly Valued?.
12:p801-p802.
2016
-
P2‐440: Utilization of Health and Community Support Services Among Alzheimer Society Caregivers and Individuals in the Early Stages of Dementia.
12:p816-p816.
2016
-
P3‐033: Results from the Achieve‐P Study: A Pilot Study for a Randomized Controlled Trial to Determine if Hearing Loss Treatment Can Reduce the Risk of Cognitive Decline in Older Adults.
12:p829-p830.
2016
-
P3‐337: Dementia Care Learning Needs Among Primary Care Clinicians: Does This Vary by Practice Setting?.
12:p975-p976.
2016
-
P3‐388: Trends in Health System use by Persons with Dementia in Ontario from 2007 and 2013: A Population‐Based Study.
12:p997-p998.
2016
-
Diagnostic value of lobar microbleeds in individuals without intracerebral hemorrhage.
11:1480-1488.
2015
-
IC‐P‐004: The association between amyloid burden and language outcomes in the wisconsin registry for Alzheimer's prevention (WRAP).
11:p14-p15.
2015
-
O2‐07‐06: The effects of computerized cognitive testing of older patients on primary care physicians' care strategies.
11:p190-p191.
2015
-
P3‐102: ApoE‐e4 allele status is associated with functional limitations in community‐dwelling older adults.
11:p659-p659.
2015
-
P4‐124: The association between amyloid burden and language outcomes in the wisconsin registry for Alzheimer's prevention (WRAP).
11:p825-p826.
2015
-
P2‐325: A COMPARISON OF HEALTH UTILITY SCORES CALCULATED USING UNITED KINGDOM AND CANADIAN PREFERENCE WEIGHTS IN AN ALZHEIMER'S DISEASE SAMPLE.
10:p598-p598.
2014
-
P3‐091: PLASMA AMYLIN LEVELS ARE ASSOCIATED WITH BRAIN STRUCTURE AMONG INDIVIDUALS WITH TYPE‐2 DIABETES.
10:p661-p661.
2014
-
O2–05–01: The social experiences of spouses of persons with young‐onset dementia (YOD): Social change, support and resiliency.
9:p324-p324.
2013
-
P1–024: Immunological dysfunction and MCI‐like behavior in the 3xTgAD mice.
9:p161-p161.
2013
-
P1–251: 25‐Hydroxyvitamin D, cognition and Alzheimer's disease.
9:p244-p244.
2013
-
P3–247: Improving access to community services: Role of the Alzheimer Society in primary care–based memory clinics.
9:p647-p647.
2013
-
PC‐007: Impact of an Alzheimer's society and primary care partnership: A survey of health care providers.
9:p118-p118.
2013
-
O3‐02‐06: “They knew who she was”: Toward an understanding of diagnosis and care of people with dementia in Aboriginal communities.
8:p431-p431.
2012
-
O3‐07‐03: Improving the system of care for older adults with dementia: Building capacity at the primary care level.
8:p443-p443.
2012
-
P3‐297: Rural Dementia Action Research (RaDAR) team: Report on a community‐based primary health care team grant planning session.
8:p563-p563.
2012
-
P3‐312: The association between caregiver and patient health‐related quality‐of‐life in Alzheimer's disease.
8:p568-p569.
2012
-
O1‐07‐07: PET and tissue autoradiography evidence of decline of metabotropic glutamate receptor type 5 (mGluR5) in the prefrontal cortex of Alzheimer's disease.
7:s111-s111.
2011
-
P3‐308: Cardiac Rehabilitation: Benefits to people with MCI and Alzheimer's disease.
7:s614-s615.
2011
-
P3‐407: Patients’ and caregivers’ willingness to pay for a new Alzheimer's disease medication.
7:s645-s646.
2011
-
Commentary on “Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.” A Canadian perspective.
7:330-332.
2011
-
IC‐P‐140: Declines of hippocampal metabotropic glutamate receptor in Alzheimer's disease.
5:p56-p57.
2009
-
O1‐01‐05: Brain microvascular fragility is a major cause of Alzheimer's disease.
5:p77-p78.
2009
-
P1‐196: Dementia in Malta: Experiences of dementia patients and their caregivers.
5:p234-p234.
2009
-
P1‐208: How does the Canadian general public view moderate Alzheimer's disease? determination of health utility scores.
5:p238-p238.
2009
-
P1‐222: Canadians’ willingness to pay for Alzheimer's disease medications: Preliminary results of a study of the general public.
5:p241-p241.
2009
-
P2‐022: Declines of hippocampal metabotropic glutamate receptor in Alzheimer's disease.
5:p267-p267.
2009
-
P2‐226: Public support for an annual tax increase to provide access to an Alzheimer's disease medication in Canada.
5:p326-p327.
2009
-
P2‐287: The impact of clinician judgment on the decision to insure a medication for Alzheimer's disease.
4:t456-t456.
2008
-
P3‐438: The role of clinician judgment in Canadian formulary committee members' recommendations to insure an Alzheimer's disease medication: Results of a pilot qualitative study.
4:t650-t650.
2008
-
General risk factors for dementia: A systematic evidence review.
3:341-347.
2007
-
Primary prevention of dementia.
3:348-354.
2007
-
P2–330: Altered brain iron metabolism as a risk factor for Alzheimer's disease.
2:s338-s338.
2006
-
P4–171: Targeting general practitioners in postal survey research on Alzheimer's disease.
2:s566-s566.
2006
-
P4–233: Care–recipient use of dementia medications and caregiver depression and overall caregiver health.
2:s585-s585.
2006
-
The reciprocal risks of stroke and cognitive impairment in an elderly population.
2:171-178.
2006
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)